Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

[Elucidating anticancer drug resistance in urothelial carcinoma by multi-faceted approach]

Original in Japanese: Elucidating anticancer drug resistance in urothelial carcinoma by multi-faceted approach

Funder: Japan Society for the Promotion of Science

Funding period
JPY 4.4 M
USD 41 K
Funding amount
Abstract
[In this study, in addition to conventional analysis based on RNA sequences and microRNA expression profiles, we will analyze metabolomics and introduce a new genome editing technology, the CRISPR library, into urothelial cancer cells. In this way, by conducting a multifaceted approach from many databases, we position the known GC resistance mechanism research, clarify the core GC resistance mechanism and explore the possibility of drug repositioning with existing drugs, It is a proposal to collect basic data for a new, inexpensive and effective treatment to overcome resistance.]
Original in Japanese
本研究では従来のRNAシーケンスやマイクロRNAの発現プロファイルに基づく解析に加えて、メタボロミクス解析や新しいゲノム編集技術であるCRISPRライブラリーを尿路上皮癌細胞に導入して解析する。これにより多くのデータベースから多面的アプローチを行うことで、既知の GC 耐性機序研究の位置づけを行うとともに、核心的なGC耐性機序を明らかにして既存薬によるドラッグリポジショニングの可能性を探り、安価で有効な新規の耐性克服治療のための基礎的データを収集する提案である。
Similar projects All >
Sorted by: Start Date
Project list item
Analysis of the antineoplastic action of Class I HDAC inhibitors to define new combination therapies for urothelial carcinoma

German Research Foundation to Günter Niegisch, Michèle Janine Hoffmann

 
2020 -
Project list item
Unravelling Mechanisms of Resistance to Checkpoint Inhibition in Canine Urothelial Carcinoma

V Foundation for Cancer Research to Nicola J. Mason

USD 500,000
2019 - 2021
Project list item
Engineering Smart Solutions for Disorders of the Bladder Urothelium

Engineering and Physical Sciences Research Council

 
2019 - 2023
Project list item
Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer

Bladder Cancer Advocacy Network to Philip A Beachy, Kris Butalid Prado

USD 300,000
2019 - 2021

System

Categories
  • FOR (ANZSRC)

    1115 Pharmacology and Pharmaceutical Sciences

  • RCDC

    Antimicrobial Resistance

  • RCDC

    Biotechnology

  • RCDC

    Cancer

  • RCDC

    Genetics

  • HRCS HC

    Cancer

  • HRCS RAC

    5.1 Pharmaceuticals

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science